Bio-Modeling Systems is the world’s first Mechanisms-Based Medicine company that successfully changed the discovery paradigm, addressing the complexity of life sciences mechanisms and the digital "garbage in garbage out" reality through CADI*™ Discovery based on Augmented Intelligence, the other complementary AI, for complex systems.
BMSystems Group addresses two complementary targets in Pharma, Biotech, Cosmetics, Nutrition and digital-Health businesses:
- R&D, Translational Medicine, & Digital Health Executives: We offer robust alternative decision-making to de-risk, save time and costs of R&D and Digital Health programs,
- Business Developers, Patients Groups & Investors: We discover novel low-risk, highly effective and cost-effective diagnostics/therapies for therapeutic spin-offs or out-licensing.
- A world's first in CNS diseases with CEA: 2 awards (US & Europe),
- Pherecydes-Pharma: First BMSystems' therapeutic spin-off, against MR infections diseases, Compassionate Use success,
- CEA/BMSystems collaborative research success in CNS that led to the co-owned therapeutic class patent with a worldwide exclusive license to a CEA’s spin-off,
- 14 R&D validated successes, 8 novel combo-therapies and combo-diagnostics ready for development,
- Mechanisms-Based Cosmetics developed to address Cosmetics business,
- GEMMA (Autism & Microbiota) H2020 program with €14.2M funding. BMSystems is the Integrative Biology Partner.
We warmly invite you to download our Short Corporate Presentation
The life-modeling issue: Are we using the right concepts in the righ order?
CADI™ : Computer Augmented Deductive Intelligence)